HeartFlow: An Impressive MedTech Growth Play

HeartFlow reported Q2 revenue growing 48% and lifted gross margins to 83%, supporting a strong re-rating of the story. The company raised full-year revenue guidance to $246–$250 million and pointed to expanding plaque-related revenue and commercial adoption of its non-invasive cardiac solution. Despite a seemingly conservative guide, the shares trade around 13x sales as momentum and topline growth accelerate.

Analysis

The setup is less about one quarter and more about whether HTFL can convert technical adoption into a durable reimbursement flywheel. At 13x sales, the market is already paying for a long runway, so the equity only compounds if utilization broadens beyond early adopters and the company keeps extracting mix toward higher-ARPU plaque-related workflows. That said, high-80s gross margin potential changes the math: incremental revenue should drop through meaningfully, which makes this one of the few medtech models where a modest step-up in volume can justify a much higher multiple.

Second-order winners are the CT imaging ecosystem and hospital systems that can monetize non-invasive triage without adding cath-lab capacity; the loser is diagnostic cath volume, especially where invasive workups are already being scrutinized by payers. Over the next 1-3 months, the key catalyst is not another press release but whether management raises the implied full-year run-rate again and whether installed-base usage expands, not just new account adds. Over 6-18 months, the thesis either becomes a standard-of-care pathway play or re-rates down if it remains a discretionary add-on.

The contrarian risk is that investors are treating conservative guidance as sandbagging, when it may simply reflect uncertainty around reimbursement cadence and adoption velocity. If growth slips back toward the 20s, or if plaque monetization turns out to be episodic rather than recurring, the multiple can compress quickly from premium medtech to expensive niche software. Falsifier: any sign in the next two quarters that gross margin stalls, guidance is not stepped up, or utilization per customer fails to improve.

Key Decisions for Investors

• Long HTFL on pullbacks over the next 2-4 weeks; thesis is multiple support from sustained >30% growth and operating leverage, with downside if the stock starts discounting a deceleration path.
• Use a 6-9 month call-spread structure in HTFL rather than an outright long if volatility is elevated; this keeps exposure to the re-rate while limiting damage if the premium multiple compresses first.
• Watch for a catalyst pair: any 1Q/2Q evidence of rising plaque mix plus another raise in implied revenue run-rate. If that does not happen, reduce exposure and assume the market will reprice HTFL toward a lower high-growth medtech multiple.
• For a hedge against pathway adoption disappointment, short a broad medtech ETF or procedural-care basket on strength rather than trying to force a single-name short; the cleaner risk is multiple compression, not company-specific collapse.